Cargando…

Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide

Advanced-stage peritoneal carcinomatosis is resistant to current chemotherapy treatment and, in the case of metastatic ovarian cancer, results in a devastating 15%–20% survival rate. Therapeutics that restore genes inactivated during oncogenesis are predicted to be more potent and specific than curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Snyder, Eric L, Meade, Bryan R, Saenz, Cheryl C, Dowdy, Steven F
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC340944/
https://www.ncbi.nlm.nih.gov/pubmed/14966535
http://dx.doi.org/10.1371/journal.pbio.0020036